tbuckley/cabot-search huggingface dataset:
Sickle Cell Trait Associated With Kidney Failure and COVID-19 Death
Authors: Anita Slomski
Journal: JAMA (2022)

Anurag Verma, PhD; Jennifer E. Huffman, PhD; Lina Gao, PhD; Jessica Minnier, PhD; Wen-Chih Wu, MD, MPH; Kelly Cho, PhD, MPH; Yuk-Lam Ho, MPH; Bryan R. Gorman, PhD; Saiju Pyarajan, PhD; Nallakkandi Rajeevan, PhD; Helene Garcon, MD; Jacob Joseph, MBBS, MD; John E. McGeary, PhD; Ayako Suzuki, MD, PhD, MSc; Peter D. Reaven, MD; Emily S. Wan, MD, MPH; Julie A. Lynch, PhD, RN; Jeffrey M. Petersen, MD; James B. Meigs, MD, MPH; Matthew S. Freiberg, MD, MSc; Elise Gatsby, MPH; Kristine E. Lynch, MS, PhD; Seyedeh Maryam Zekavat, BS; Pradeep Natarajan, MD, MMSc; Sharvari Dalal, MD; Darshana N. Jhala, MD, BMus; Mehrdad Arjomandi, MD; Robert A. Bonomo, MD; Trevor K. Thompson; Gita A. Pathak, PhD; Jin J. Zhou, PhD; Curtis J. Donskey, MD; Ravi K. Madduri, MS; Quinn S. Wells, MD, PharmD; Joel Gelernter, MD; Rose D. L. Huang, MS; Renato Polimanti, PhD; Kyong-Mi Chang, MD; Katherine P. Liao, MD, MPH; Philip S. Tsao, PhD; Yan V. Sun, PhD; Peter W. F. Wilson, MD; Christopher J. O’Donnell, MD, MPH; Adriana M. Hung, MD; J. Michael Gaziano, MD; Richard L. Hauger, MD; Sudha K. Iyengar, PhD; Shiuh-Wen Luoh, MD, PhD; VA Million Veteran Program COVID-19 Science Initiative; Sumitra Muralidhar; Jean Beckham; Jennifer Moser; Lauren Thomann; Helene Garcon; Nicole Kosik; Scott D. Damrauer; Themistocles Assimes; Panagiotis Roussos; Robert Striker; Sony Tuteja; Scott L. DuVall; Kristine E. Lynch; Elise Gatsby; Rachel Ramoni; James Breeling; Grant Huang; Stacey B. Whitbourne; Jessica V. Brewer; Mihaela Aslan; Todd Connor; Dean P. Argyres; Brady Stephens; Mary T. Brophy; Donald E. Humphries; Luis E. Selva; Nhan Do; Shahpoor (Alex) Shayan; Lori Churby; Elizabeth Hauser; Hongyu Zhao; Peter Wilson; Rachel McArdle; Louis Dellitalia; Kristin Mattocks; John Harley; Jeffrey Whittle; Frank Jacono; John Wells; Salvador Gutierrez; Gretchen Gibson; Kimberly Hammer; Laurence Kaminsky; Gerardo Villareal; Scott Kinlay; Junzhe Xu; Mark Hamner; Roy Mathew; Sujata Bhushan; Pran Iruvanti; Michael Godschalk; Zuhair Ballas; Douglas Ivins; Stephen Mastorides; Jonathan Moorman; Saib Gappy; Jon Klein; Nora Ratcliffe; Hermes Florez; Olaoluwa Okusaga; Maureen Murdoch; Peruvemba Sriram; Shing S Yeh; Neeraj Tandon; Darshana Jhala; Samuel Aguayo; David Cohen; Satish Sharma; Suthat Liangpunsakul; Kris A Oursler; Mary Whooley; Sunil Ahuja; Joseph Constans; Paul Meyer; Jennifer Greco; Michael Rauchman; Richard Servatius; Melinda Gaddy; Agnes Wallbom; Timothy Morgan; Todd Stapley; Scott Sherman; George Ross; Philip Tsao; Patrick Strollo; Edward Boyko; Laurence Meyer; Samir Gupta; Mostaqul Huq; Joseph Fayad; Adriana Hung; Jack Lichy; Robin Hurley; Brooks Robey
Wisdom
Authors: Joseph Bathanti
Journal: JAMA (2022)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Diagnosis, Treatment, and Prevention of Malaria in the US
Authors: Johanna P. Daily, Aurelia Minuti, Nazia Khan
Journal: JAMA (2022)

<h3>Importance</h3> Malaria is caused by protozoa parasites of the genus<i>Plasmodium</i>and is diagnosed in approximately 2000 people in the US each year who have returned from visiting regions with endemic malaria. The mortality rate from malaria is approximately 0.3% in the US and 0.26% worldwide. <h3>Observations</h3> In the US, most malaria is diagnosed in people who traveled to an endemic region. More than 80% of people diagnosed with malaria in the US acquired the infection in Africa. Of the approximately 2000 people diagnosed with malaria in the US in 2017, an estimated 82.4% were adults and about 78.6% were Black or African American. Among US residents diagnosed with malaria, 71.7% had not taken malaria chemoprophylaxis during travel. In 2017 in the US,<i>P falciparum</i>was the species diagnosed in approximately 79% of patients, whereas<i>P vivax</i>was diagnosed in an estimated 11.2% of patients. In 2017 in the US, severe malaria, defined as vital organ involvement including shock, pulmonary edema, significant bleeding, seizures, impaired consciousness, and laboratory abnormalities such as kidney impairment, acidosis, anemia, or high parasitemia, occurred in approximately 14% of patients, and an estimated 0.3% of those receiving a diagnosis of malaria in the US died.<i>P falciparum</i>has developed resistance to chloroquine in most regions of the world, including Africa. First-line therapy for<i>P falciparum</i>malaria in the US is combination therapy that includes artemisinin. If<i>P falciparum</i>was acquired in a known chloroquine-sensitive region such as Haiti, chloroquine remains an alternative option. When artemisinin-based combination therapies are not available, atovaquone-proguanil or quinine plus clindamycin is used for chloroquine-resistant malaria.<i>P vivax, P ovale, P malariae,</i>and<i>P knowlesi</i>are typically chloroquine sensitive, and treatment with either artemisinin-based combination therapy or chloroquine for regions with chloroquine-susceptible infections for uncomplicated malaria is recommended. For severe malaria, intravenous artesunate is first-line therapy. Treatment of mild malaria due to a chloroquine-resistant parasite consists of a combination therapy that includes artemisinin or chloroquine for chloroquine-sensitive malaria.<i>P vivax</i>and<i>P ovale</i>require additional therapy with an 8-aminoquinoline to eradicate the liver stage. Several options exist for chemoprophylaxis and selection should be based on patient characteristics and preferences. <h3>Conclusions and Relevance</h3> Approximately 2000 cases of malaria are diagnosed each year in the US, most commonly in travelers returning from visiting endemic areas. Prevention and treatment of malaria depend on the species and the drug sensitivity of parasites from the region of acquisition. Intravenous artesunate is first-line therapy for severe malaria.
Association Between Dialysis Facility Ownership and Access to the Waiting List and Transplant in Pediatric Patients With End-stage Kidney Disease in the US
Authors: Sandra Amaral, Charles E. McCulloch, Feng Lin, Barbara A. Grimes, Susan Furth, Bradley Warady, Celina Brunson, Salpi Siyahian, Elaine Ku
Journal: JAMA (2022)

Care of adults at profit vs nonprofit dialysis facilities has been associated with lower access to transplant. Whether profit status is associated with transplant access for pediatric patients with end-stage kidney disease is unknown.To determine whether profit status of dialysis facilities is associated with placement on the kidney transplant waiting list or receipt of kidney transplant among pediatric patients receiving maintenance dialysis.This retrospective cohort study reviewed the US Renal Data System records of 13 333 patients younger than 18 years who started dialysis from 2000 through 2018 in US dialysis facilities (followed up through June 30, 2019).Time-updated profit status of dialysis facilities.Cox models, adjusted for clinical and demographic factors, were used to examine time to wait-listing and receipt of kidney transplant by profit status of dialysis facilities.A total of 13 333 pediatric patients who started receiving maintenance dialysis were included in the analysis (median age, 12 years [IQR, 3-15 years]; 6054 females [45%]; 3321 non-Hispanic Black patients [25%]; 3695 Hispanic patients [28%]). During a median follow-up of 0.87 years (IQR, 0.39-1.85 years), the incidence of wait-listing was lower at profit facilities than at nonprofit facilities, 36.2 vs 49.8 per 100 person-years, respectively (absolute risk difference, -13.6 (95% CI, -15.4 to -11.8 per 100 person-years; adjusted hazard ratio [HR] for wait-listing at profit vs nonprofit facilities, 0.79; 95% CI, 0.75-0.83). During a median follow-up of 1.52 years (IQR, 0.75-2.87 years), the incidence of kidney transplant (living or deceased donor) was also lower at profit facilities than at nonprofit facilities, 21.5 vs 31.3 per 100 person-years, respectively; absolute risk difference, -9.8 (95% CI, -10.9 to -8.6 per 100 person-years) adjusted HR for kidney transplant at profit vs nonprofit facilities, 0.71 (95% CI, 0.67-0.74).Among a cohort of pediatric patients receiving dialysis in the US from 2000 through 2018, profit facility status was associated with longer time to wait-listing and longer time to kidney transplant.
Improving Quality of Care and Outcomes for Pediatric Patients With End-stage Kidney Disease
Authors: Mary B. Leonard, Paul C. Grimm
Journal: JAMA (2022)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Cancer Incidence Among Adults With HIV in a Population-Based Cohort in Korea
Authors: Boyoung Park, Kyoung Hwan Ahn, Yunsu Choi, Jung Ho Kim, Hye Seong, Youn Jeong Kim, Jun Young Choi, Joon Young Song, Eunjung Lee, Yoon Hee Jun, Young Kyung Yoon, Won Suk Choi, Myungsun Lee, Jaehyun Seong, Shin-Woo Kim
Journal: JAMA Network Open (2022)

Importance In combination with a decreased risk of AIDS-defining cancers and improved survival of people infected with HIV, the burden of non–AIDS-defining cancer has increased markedly. Although a substantial number of studies have measured the cancer risk among people with HIV in developed countries, little research has been conducted on the risk of cancer in HIV-infected people in Asia. Objective To examine the cancer incidence and the estimated risk of cancer among people in Korea infected with HIV compared with the general population. Design, Setting, and Participants This retrospective cohort study evaluated patients without cancer newly diagnosed with HIV from January 1, 2006, to December 31, 2018, using a nationwide population-based claims database embedded in the National Health Insurance Service database. Data were analyzed between December 6, 2021, and February 28, 2022. Exposures Infection with HIV. Main Outcomes and Measures Cancer incidence and standardized incidence rate (SIR) through indirect standardization. Results A total of 11 552 individuals without cancer (10 444 male [90.4%]; mean [SD] age, 39.9 [11.2] years) diagnosed with HIV were identified. The SIR for all cancers was 1.68 (95% CI, 1.50-1.87) in men and 1.26 (95% CI, 0.89-1.64) in women. In men, the highest SIRs were for Kaposi sarcoma (SIR, 349.10; 95% CI, 196.10-502.20) and anal cancer (SIR, 104.20; 95% CI, 55.56-149.90). The incidence of non-Hodgkin lymphoma (SIR, 15.62; 95% CI, 11.85-19.39), Hodgkin lymphoma (SIR, 16.67; 95% CI, 4.32-29.02), and oropharyngeal cancer (SIR, 2.97; 95% CI, 1.36-4.58) in men infected with HIV was higher than in the general population. In women infected with HIV, an increased incidence of cervical cancer (SIR, 4.98; 95% CI, 1.29-8.66) and non-Hodgkin lymphoma (SIR, 11.78; 95% CI, 2.35-21.21) compared with the general population was observed. The SIR of thyroid cancer in patients with HIV was lower than in the general population in both men (SIR, 0.63; 95% CI, 0.27-0.99) and women (SIR, 0.48; 95% CI, 0.06-0.90). Conclusions and Relevance In this cohort study, cancer risks, especially AIDS-defining cancer and virus-related cancer, were elevated in people with HIV. Efforts for cancer prevention, screening, and better accessibility to medical care in HIV-infected people are warranted.
Highlights from Recent Cancer Literature
Journal: Cancer Research (2018)

MAPK AgainCisplatin is one of the most widely used chemotherapeutics, however, development of resistance often leads to tumor recurrence.Jin and colleagues identified and validated the microtubuleassociated serine/threonine kinase 1 (MAST1) as a driver of cisplatin resistance in cancers.MAST1 was identified through a kinome-wide RNAi screen in cisplatin-resistant carcinoma cells.Although this kinase is part of the cRaf-MEK1 complex, cancer cells depend on cRAf-dependent MEK1 activation to proliferate.Cisplatin treatment dissociated cRaf from MEK1, enabling MAST1 to phosphorylate and reactivate MEK1.MAST1 and MAPK activation correlated with cisplatin resistance and poor outcome in several cancer types.The multikinase inhibitor, lestaurtinib, inhibited MAST1 and restored sensitivity to platinum compounds.Combining lestaurtinib or a MEK inhibitor with cisplatin synergistically inhibited growth of primary platinum-resistant cancer cells.Expert Commentary: This study demonstrates yet another mechanism by which ultimately the MAPK pathway may serve as a conduit for treatment refractoriness in cancer.(Image courtesy of Wikimedia
Response to Concerns Raised About the New American Academy of Pediatrics Febrile Infant Guideline
Authors: Robert H. Pantell, Kenneth B. Roberts, Benard P. Dreyer
Journal: JAMA Pediatrics (2022)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Pediatrics HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Pediatrics journal
Ionic liquid-mediated delivery of a BCL-2 inhibitor for topical treatment of skin melanoma
Authors: Md Nurul Huda, Isaac G. Deaguero, Edgar A. Borrego, Raj Kumar, Tamanna Islam, Humayra Afrin, Armando Varela-Ramirez, Renato J. Aguilera, Eden E.L. Tanner, Md Nurunnabi
Journal: Journal of Controlled Release (2022)
Breast cancer vaccines: New insights into immunomodulatory and nano-therapeutic approaches
Authors: Fatemeh Davodabadi, Mohammad Sarhadi, Javad Arabpour, Saman Sargazi, Abbas Rahdar, Ana M. Díez-Pascual
Journal: Journal of Controlled Release (2022)

Breast cancer (BC) is known to be a highly heterogeneous disease that is clinically subdivided into four primary molecular subtypes, each having distinct morphology and clinical implications. These subtypes are principally defined by hormone receptors and other proteins involved (or not involved) in BC development. BC therapeutic vaccines [including peptide-based vaccines, protein-based vaccines, nucleic acid-based vaccines (DNA/RNA vaccines), bacterial/viral-based vaccines, and different immune cell-based vaccines] have emerged as an appealing class of cancer immunotherapeutics when used alone or combined with other immunotherapies. Employing the immune system to eliminate BC cells is a novel therapeutic modality. The benefit of active immunotherapies is that they develop protection against neoplastic tissue and readjust the immune system to an anti-tumor monitoring state. Such immunovaccines have not yet shown effectiveness for BC treatment in clinical trials. In recent years, nanomedicines have opened new windows to increase the effectiveness of vaccinations to treat BC. In this context, some nanoplatforms have been designed to efficiently deliver molecular, cellular, or subcellular vaccines to BC cells, increasing the efficacy and persistence of anti-tumor immunity while minimizing undesirable side effects. Immunostimulatory nano-adjuvants, liposomal-based vaccines, polymeric vaccines, virus-like particles, lipid/calcium/phosphate nanoparticles, chitosan-derived nanostructures, porous silicon microparticles, and selenium nanoparticles are among the newly designed nanostructures that have been used to facilitate antigen internalization and presentation by antigen-presenting cells, increase antigen stability, enhance vaccine antigenicity and remedial effectivity, promote antigen escape from the endosome, improve cytotoxic T lymphocyte responses, and produce humoral immune responses in BC cells. Here, we summarized the existing subtypes of BC and shed light on immunomodulatory and nano-therapeutic strategies for BC vaccination. Finally, we reviewed ongoing clinical trials on BC vaccination and highlighted near-term opportunities for moving forward.
Abstract Book of ISHL11 October 27‐29, 2018
Journal: HemaSphere (2018)

Log in or Register Get new issue alertsGet alerts Submit your manuscript Enter your Email address: Wolters Kluwer Health may email you for journal alerts and information, but is committed to maintaining your privacy and will not share your personal information without your express consent. For more information, please refer to our Privacy Policy. Subscribe to eTOC Secondary Logo Journal Logo All Articles Images Videos Podcasts Blogs Advanced Search Toggle navigation Register Login Articles & Issues Latest ArticlesCurrent IssuePrevious Issues Subject Areas Cell and Gene TherapiesHematopoiesisLymphoid MalignanciesMyeloid MalignanciesRed Cell and Iron MetabolismThrombosis and HemostasisView All Featured Content Latest ArticlesReviews & ControversiesGuidelinesHemaTopicsHemaBitesEHA Research RoadmapCAR T-CellGene TherapyCOVID-19Biosimilars For Authors Instructions for Authors Submit Your PaperBenefits for AuthorsOpen Access Editorial, Legal, and Ethical PoliciesLanguage Editing Services About Us About the JournalEditorial BoardAffiliated SocietyReprintsRights and Permissions All Articles Images Videos Podcasts Blogs Advanced Search
Endoscopy International Open – recently published
Journal: Endoscopy (2018)

Comment on: Endoscopic full-thickness resection of polyps involving the appendiceal orifice: a prospective observational case studyEndosc Int Open 2018; 06(09): E1112-E1119DOI: 10.1055/a-0635-0911 Comment on: Endoscopic augmentation of gastroesophageal junction using a full-thickness endoscopic suturing deviceEndosc Int Open 2018; 06(09): E1120-E1125DOI: 10.1055/a-0603-3693 Comment on: Endoscopic submucosal dissection for early squamous cell carcinoma in the anal canal and Lugol chromoendoscopy for assessment of the lateral marginEndosc Int Open 2018; 06(09): E1130-E1133DOI: 10.1055/a-0584-7060
A multi-platform reference for somatic structural variation detection
Authors: Jose Espejo Valle-Inclan, Nicolle J.M. Besselink, Ewart de Bruijn, Daniel L. Cameron, Jana Ebler, Joachim Kutzera, Stef van Lieshout, Tobias Marschall, Marcel Nelen, Peter Priestley, Ivo Renkens, Margaretha G.M. Roemer, Markus J. van Roosmalen, Aaron M. Wenger, Bauke Ylstra, Remond J.A. Fijneman, Wigard P. Kloosterman, Edwin Cuppen
Journal: Cell Genomics (2022)

Accurate detection of somatic structural variation (SV) in cancer genomes remains a challenging problem. This is in part due to the lack of high-quality, gold-standard datasets that enable the benchmarking of experimental approaches and bioinformatic analysis pipelines. Here, we performed somatic SV analysis of the paired melanoma and normal lymphoblastoid COLO829 cell lines using four different sequencing technologies. Based on the evidence from multiple technologies combined with extensive experimental validation, we compiled a comprehensive set of carefully curated and validated somatic SVs, comprising all SV types. We demonstrate the utility of this resource by determining the SV detection performance as a function of tumor purity and sequence depth, highlighting the importance of assessing these parameters in cancer genomics projects. The truth somatic SV dataset as well as the underlying raw multi-platform sequencing data are freely available and are an important resource for community somatic benchmarking efforts.